JP2023528002A5 - - Google Patents
Info
- Publication number
- JP2023528002A5 JP2023528002A5 JP2022572706A JP2022572706A JP2023528002A5 JP 2023528002 A5 JP2023528002 A5 JP 2023528002A5 JP 2022572706 A JP2022572706 A JP 2022572706A JP 2022572706 A JP2022572706 A JP 2022572706A JP 2023528002 A5 JP2023528002 A5 JP 2023528002A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific molecule
- surface antigen
- binding
- optionally
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030714P | 2020-05-27 | 2020-05-27 | |
| US63/030,714 | 2020-05-27 | ||
| PCT/US2021/034526 WO2021243028A1 (en) | 2020-05-27 | 2021-05-27 | Bispecific molecules for selectively modulating t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528002A JP2023528002A (ja) | 2023-07-03 |
| JP2023528002A5 true JP2023528002A5 (https=) | 2024-05-31 |
Family
ID=78722762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572706A Pending JP2023528002A (ja) | 2020-05-27 | 2021-05-27 | Ｔ細胞を選択的に調節するための二重特異性分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230203157A1 (https=) |
| EP (1) | EP4157354A4 (https=) |
| JP (1) | JP2023528002A (https=) |
| KR (1) | KR20230029611A (https=) |
| AU (1) | AU2021279028A1 (https=) |
| CA (1) | CA3177550A1 (https=) |
| WO (1) | WO2021243028A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118027197A (zh) | 2017-07-06 | 2024-05-14 | 美勒斯公司 | 调节由细胞表达的生物活性的抗体 |
| KR20230163503A (ko) | 2021-03-31 | 2023-11-30 | 메뤼스 엔.페. | 신규한 pd-1 결합 도메인 |
| KR20240099460A (ko) | 2021-11-11 | 2024-06-28 | 리제너론 파아마슈티컬스, 인크. | Cd20-pd1 결합 분자 및 이의 사용 방법 |
| WO2024156006A2 (en) * | 2023-01-20 | 2024-07-25 | New York University | Targeting mhc-i antigen presentation modulators for immunotherapy for cancer and autoimmune disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996009380A1 (en) * | 1994-09-23 | 1996-03-28 | The University Of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| NO2344540T3 (https=) * | 2008-10-02 | 2018-04-28 | ||
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| BR112018006817A2 (pt) * | 2015-10-08 | 2018-10-23 | Macrogenics Inc | método de tratamento do câncer |
| EP3426688A1 (en) * | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
| EP3596108A4 (en) * | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| WO2019062755A1 (en) * | 2017-09-29 | 2019-04-04 | Wuxi Biologics (Shanghai) Co., Ltd. | BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1 |
| WO2019153200A1 (zh) * | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| WO2020018715A1 (en) * | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
-
2021
- 2021-05-27 KR KR1020227041949A patent/KR20230029611A/ko active Pending
- 2021-05-27 JP JP2022572706A patent/JP2023528002A/ja active Pending
- 2021-05-27 WO PCT/US2021/034526 patent/WO2021243028A1/en not_active Ceased
- 2021-05-27 US US17/927,529 patent/US20230203157A1/en active Pending
- 2021-05-27 EP EP21813720.6A patent/EP4157354A4/en active Pending
- 2021-05-27 CA CA3177550A patent/CA3177550A1/en active Pending
- 2021-05-27 AU AU2021279028A patent/AU2021279028A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2023528002A5 (https=) | ||
| RU2644686C2 (ru) | Идентификация опухолеассоциированных антигенов для диагностики и терапии | |
| KR102363742B1 (ko) | Cd19에 대한 인간화 항원-결합 도메인 및 사용 방법 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| JP2020504095A (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2019509055A (ja) | 多特異性免疫調節抗原結合構築物 | |
| JP2021518133A5 (https=) | ||
| EP4157354A1 (en) | Bispecific molecules for selectively modulating t cells | |
| WO2006075784A1 (ja) | 抗α９インテグリン抗体とその用途 | |
| JP2018532427A (ja) | 抗ｃｄ９５ｌ抗体 | |
| JP5566374B2 (ja) | 形質細胞の腫瘍性増殖をきたす疾患の治療薬 | |
| CN110615841B (zh) | 抗人cd47单克隆抗体及其应用 | |
| CN109593135B (zh) | 抗人pd-l1单克隆抗体及其应用 | |
| RU2802272C2 (ru) | Антитело к cd3 и его фармацевтическое применение | |
| JP2026058690A (ja) | 抗ｕｌｂｐ２抗体 | |
| CN120718148A (zh) | 一种抗cd38纳米抗体及其制备方法与应用 | |
| HK40103404A (zh) | 用於产生个人化癌症免疫疗法的方法 | |
| HK40088602A (zh) | 结合tnfr2的抗体及其用途 | |
| EA052990B1 (ru) | Химерный антигенный рецептор антител к hk2 (car) | |
| HK40051452B (en) | Cd3 antibody and pharmaceutical use thereof | |
| KR20190107967A (ko) | 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법 | |
| HK1168609A (en) | Identification of tumor-associated antigens for diagnosis and therapy | |
| HK1168610A (en) | Identification of tumor-associated antigens for diagnosis and therapy |